Lyra Therapeutics (LYRA) News Today $6.40 +0.07 (+1.03%) Closing price 03:58 PM EasternExtended Trading$6.39 0.00 (-0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Lyra Therapeutics Receives Nasdaq Deficiency LetterAugust 23, 2025 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lyra Therapeutics (LYRA), Stoke Therapeutics (STOK) and Astria Therapeutics (ATXS)August 14, 2025 | theglobeandmail.comLyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production ShiftAugust 14, 2025 | tipranks.comLyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)August 12, 2025 | msn.comLyra Therapeutics Posts 85% Q2 Loss DropAugust 12, 2025 | theglobeandmail.comLyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comLyra Therapeutics Board Chair Waksal Steps DownAugust 2, 2025 | marketwatch.comLyra Therapeutics Announces Leadership Changes in August 2025August 2, 2025 | msn.comLyra Therapeutics, Inc. (NASDAQ:LYRA) CEO Sells $13,944.15 in StockJuly 15, 2025 | insidertrades.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and Warrants - NasdaqJune 29, 2025 | nasdaq.comLyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%June 27, 2025 | msn.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and WarrantsJune 27, 2025 | quiverquant.comQLyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesJune 27, 2025 | globenewswire.comLyra Therapeutics Regains Nasdaq Compliance in June 2025June 23, 2025 | tipranks.comLyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated CatalystJune 16, 2025 | seekingalpha.comH.C. Wainwright lifts Lyra Therapeutics stock target to $16June 11, 2025 | investing.comLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in ...June 4, 2025 | seekingalpha.comLyra Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:LYRA | BenzingaJune 3, 2025 | benzinga.comLyra Therapeutics (NASDAQ:LYRA) Stock, Insider Trading ActivityJune 3, 2025 | benzinga.comLyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s ThrilledJune 2, 2025 | msn.comWall Street drifts higher as oil prices jump and US manufacturing slumpsJune 2, 2025 | msn.comLyra Therapeutics Shares Skyrocket on Strong Phase 3 Results for CRS TreatmentJune 2, 2025 | msn.comLyra Therapeutics Shares Climb Over 500% After Major CRS Trial WinJune 2, 2025 | finance.yahoo.comWhy Is Lyra Therapeutics Stock Surging Over 400% On Monday?June 2, 2025 | benzinga.comLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)June 2, 2025 | globenewswire.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Sees Large Decrease in Short InterestMay 30, 2025 | marketbeat.comLyra Therapeutics trading halted, news pendingMay 28, 2025 | msn.comLyra Therapeutics Reports Q1 2025 Financial ResultsMay 13, 2025 | tipranks.comLyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025May 7, 2025 | globenewswire.comLyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comLyra Therapeutics Reports 2024 Financial Results and UpdatesMarch 14, 2025 | tipranks.comLyra Therapeutics (LYRA) Gets a Hold from William BlairMarch 14, 2025 | markets.businessinsider.comLyra Therapeutics reports Q4 EPS ($1.43), consensus (13c)March 13, 2025 | markets.businessinsider.comLyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comZevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue EstimatesMarch 11, 2025 | msn.comLyra Therapeutics Pursues ENLIGHTEN 2 Trial for LYR-210January 10, 2025 | markets.businessinsider.comLyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial OutcomesNovember 15, 2024 | markets.businessinsider.comLyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 14, 2024 | finance.yahoo.comLyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comLyra Therapeutics, Inc. (LYRA)October 22, 2024 | finance.yahoo.comLyra Therapeutics completes Phase 3 trial enrollment for CRS treatmentOctober 17, 2024 | uk.investing.comLyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisOctober 15, 2024 | globenewswire.comLyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsSeptember 27, 2024 | globenewswire.comLyra Therapeutics Insiders Still US$66k Away From Original Investment ValueAugust 22, 2024 | uk.finance.yahoo.comLyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comCeltic academy graduate Lawal makes permanent switch to StokeAugust 12, 2024 | bbc.comBLyra Therapeutics, Inc. (LYRA) latest stock news & headlines – Yahoo FinanceJuly 19, 2024 | nz.finance.yahoo.comLyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?July 15, 2024 | insidermonkey.comMaintaining Hold on ProKidney: Balancing Market Potential Against Clinical UncertaintiesMay 28, 2024 | markets.businessinsider.comLyra to cut 75% of workforce in portfolio shakeupMay 21, 2024 | msn.com Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYRA Media Mentions By Week LYRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYRA News Sentiment▼1.910.93▲Average Medical News Sentiment LYRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYRA Articles This Week▼11▲LYRA Articles Average Week Get the Latest News and Ratings for LYRA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lyra Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NEPH News Today NMTC News Today MODD News Today TMDIF News Today ECOR News Today CLGN News Today POCI News Today RBOT News Today STRR News Today VVOS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYRA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
